| Autor: |
Shaikh, Preet A., Som, Avira, Deych, Elena, Deng, Alison J., Reimers, Melissa A., Baumann, Brian C., Kim, Eric H., Lenihan, Daniel J., Zhang, Kathleen W. |
| Předmět: |
|
| Zdroj: |
Clinical Genitourinary Cancer; Apr2024, Vol. 22 Issue 2, p586-592, 7p |
| Abstrakt: |
Cardiovascular (CV) disease is the leading cause of death in men with prostate cancer, and practical tools are needed to facilitate CV risk stratification within oncology practice. Among 354 men with recurrent prostate cancer undergoing PET/CT at a single institution, incidental coronary calcification was associated with major adverse CV event with greater feasibility than the Framingham risk score. Background: Cardiovascular (CV) disease is common among men with prostate cancer and the leading cause of death in this population. There is a need for CV risk assessment tools that can be easily implemented in the prostate cancer treatment setting. Methods: Consecutive patients who underwent positron emission tomography/computed tomography (PET/CT) for recurrent prostate cancer at a single institution from 2012 to 2017 were identified retrospectively. Clinical data and coronary calcification on nongated CT imaging were obtained. The primary outcome was major adverse CV event (MACE; myocardial infarction, coronary or peripheral revascularization, stroke, heart failure hospitalization, or all-cause mortality) occurring within 5 years of PET/CT. Results: Among 354 patients included in the study, there were 98 MACE events that occurred in 74 patients (21%). All-cause mortality was the most common MACE event (35%), followed by coronary revascularization/myocardial infarction (26%) and stroke (19%). Coronary calcification was predictive of MACE (HR = 1.9, 95% CI: 1.1-3.4, P = .03) using adjusted Kaplan-Meier analysis. As a comparator, the Framingham risk score was calculated for 198 patients (56%) with complete clinical and laboratory data available. In this subgroup, high baseline Framingham risk (corresponding to 10-year risk of CV disease > 20%) was not predictive of MACE. Conclusions: MACE was common (21%) in men with recurrent prostate cancer undergoing PET/CT over 5 years of follow-up. Incidental coronary calcification on PET/CT was associated with increased risk of MACE and may have utility as a CV risk predictor that is feasible to implement among all prostate cancer providers. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full Text from ScienceDirect